Real value shared with the global community
2024 – Findings from expert oncologists indicate that Dave provides valuable and reliable recommendations to patients living with a wide range of cancers.
Belong
provides
True value for the global
community
Advance clinical research and improve quality of patient life and care. Belong’s proprietary, multi-layered data is powered by advanced machine learning and artificial intelligence.. For patients, caregivers, health professionals, providers and pharma.
We are deeply committed to advancing the state of global research with quality, real-world data.
Leveraging AI & ML
for a Hyper-Personalized
Experience
By understanding real-life treatment journeys, analyzing critical decision points, conducting surveys, and providing you with competitive Business Intelligence.
We have made significant contributions to global cancer research, having published several papers in leading international peer-reviewed journals.
2024 – Findings from expert oncologists indicate that Dave provides valuable and reliable recommendations to patients living with a wide range of cancers.
2024 – This important validation, conducted by leading oncologists, supports the accuracy and reliability of the AI-powered Cancer Mentor in addressing the complex questions and needs of people diagnosed with cancer.
2024 – Cancer patients’ real-world-behavior reveals compromised daily life activities, which are likely attributed to misconceptions about therapy and disease.
2024 – Realistic trends in patients self-set weight loss goals, considering obesity related comorbidities and the use of anti-obesity medications.
RWD showed that in cancer patients using cannabis, the rate of reported symptomatic tachy- and brady-arrhythmias was significant but rarely led to invasive treatments.
International Survey Conducted by Belong.Life and the Tel Aviv Sourasky Medical Center Highlights Need for Real-life Quality of Life Assessments as Additional Endpoints in Clinical Trials.
71% of Cancer Patients Unaware of Heightened Thrombosis Risks Associated with Cancer.
2022
87.5% of health care providers agree that the Belong.life App helps their patients manage their health. 57% felt that it had prevented Emergency Room visits.
Covid 19 infection leading to a subsequent new primary cancer diagnosis, Real-world data (RWD) analysis on members of Belong.life, a global cancer application. (Abstract e18775).
Cannabis consumption has been shown to cause arrhythmias with various ambiguous combinations, including ventricular tachycardia, and potentially sudden death.
Clinical Trials Participation Is Directly Influenced By The Information Received By Cancer Patients (Pts) A Caregivers: Real-World Evidence With The Use Of A Specialized Digital Health Platform. (Abstract E24118)
Evaluating The Dyadic Management Of Sexuality-Related Parameters In Women With Early Breast Cancer (EBC): The Emergence Of “Partner Reported Outcome Measurements”. (Abstract E18779)
Researched by Belong.Life and published by ASCO
1069 patients, users of Belong.life, a worldwide, free, and voluntary, digital health application,
replied during April 2021 to a targeted survey including demographic & clinical questions
related to their cancer status, ongoing therapies and the received Covid 19 vaccination details
2020
Social media platforms give patients a voice by allowing them to discuss their health and connect with others. These unfiltered and genuine reports offer direct access to what matters most to patients. Exploring the patient-reported outcomes discussed in these platforms reveal clinical insights and behavioral patterns of the real-world patient journey. This research study reviewed health-related quality of life (HRQoL) concepts reported by patients with multiple myeloma (MM).
2020
Researched by Belong.Life and published by ASCO – SITC
RWED of financial toxicity was reported by the majority of cancer pts receiving Immunotherapy drugs for treatment of their solid tumors. 48% of the pts were aware of possible FTs as a result of their diagnosis and therapy…
Researched by Belong.Life and published by ASCO
Key Findings : BRCA testing should be recommended for all pts with recently diagnosed BC and OC and in those with a higher chance of having a mutation, as defined by the USPSTF guidelines…
2019
Researched By Belong.Life with JGH and Presented by McGill University
See the latest study that was conducted by McGill University and the Jewish General Hospital in Toronto, Canada, using the Belong.life platform.
2019
A targeted survey of Belong.life Advanced Breast Cancer (ABC) patients (pts), focusing on patient’s reported outcomes (PROs), real world evidence (RWE) and insights in reducing the burden of financial toxicity (FT)
medicine, financial toxicity (FT) is a term used to describe economic problems a patient has related to the cost of medical care. Financial toxicity is an emerging and growing concern for many cancer patients.
Researched by Belong.Life and published by ASCO
Value-based healthcare requires integration of real-world data (RWD) generated by patients in parallel to clinical documentation…
Researched by Belong.Life and published by ASCO
Taxanes-induced neuropathy is common in BC patients receiving taxanes, forcing dose reductions and treatment delays and posing serious challenges for the long-term patient QoL….
Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post …
Researched by Belong.Life and published by ASCO
Identifying the patient journey and treatment lines patterns in metastatic pancreatic cancer Data from patients using the Belong PPN was able to …
Researched by Belong.Life and published by ESMO
Fatigue is a common symptom reported by cancer patients (pts) and has been previously documented to affect patient’s quality of life…
Real value shared with the global community
Belong.Life is a global leader in digital health, revolutionizing the patient experience and delivering unparalleled value for patients, healthcare providers, pharmaceutical companies, and payers.
Belong’s key solutions include the world’s largest social and professional networks for people living with cancer (Belong – Beating Cancer Together) and multiple sclerosis (BelongMS), and the BelongAI health-grade patient engagement and support platforms including Dave AI Cancer Mentor medically validated by renowned oncologists at ASCO and ESMO, Sophie– AI MS Mentor, Tara – AI Clinical Trials Matching Assistant and Fred – AI Weight and Health Mentor, which utilizes AI to proactively support and empower patients throughout their healthcare journey.
